Novartis Reinforces Commitment to Molecular Glue Approach
In recent biotech developments, Novartis has reaffirmed its focus on molecular glue strategies amidst rising drug costs for seniors and advancements in leukemia treatments.
Editorial Staff
1 min read
Updated about 6 hours ago
Novartis has recently emphasized its dedication to molecular glue strategies, a significant move in the biotech sector.
This announcement comes at a time when drug costs for seniors are reportedly increasing sharply, raising concerns about accessibility.
Additionally, developments in leukemia treatments, particularly from companies like Enliven, are also making headlines in the industry.